Targacept.

• Position: Statewide - Acquisition of Targacept - Brief article

WINSTON-SALEM--Catalyst Biosciences will acquire Targacept in a reverse merger that will allow Catalyst to become a publicly traded company. Targacept was formed in 1997 as a subsidiary of R.J. Reynolds Tobacco and develops treatments for nervous-system and gastrointestinal disorders. It went public in 2006 and traded as high as $30 in 2011, but never...